A large body of literature documents the adverse effects of maternal depression on the
functioning and development of offspring. Although investigators have identified factors …

OBJECTIVE: To address the maternal and neonatal risks of both depression and
antidepressant exposure and develop algorithms for periconceptional and antenatal …

Importance Untreated depression during pregnancy has been associated with increased
morbidity and mortality for both mother and child and, as such, optimal treatment strategies …

Before marketing a new drug, the manufacturer almost never tests the product in pregnant
women to determine its effects on the fetus. Consequently, most drugs are not labeled for …

Background Although fluoxetine is the most frequently prescribed antidepressant drug in the
United States, its safety in pregnant women has not been established. Methods From 1989 …

Epidemiologic data from around the world demonstrate that major depression is
approximately twice as common in women than men and that its first onset peaks during the …

Context Prenatal exposure to selective serotonin reuptake inhibitor (SSRI) antidepressants
and maternal depression both alter neonatal health, and distinguishing the effects of each …

Objective: Selective serotonin reuptake inhibitor (SSRI) use during pregnancy incurs a low
absolute risk for major malformations; however, other adverse outcomes have been …

Weight gain during antidepressant treatment can be either a sign of improvement in patients
who have weight loss as a symptom of depression or a residual symptom in patients who …

Background The risk of birth defects after antenatal exposure to selective serotonin-reuptake
inhibitors (SSRIs) remains controversial. Methods We assessed associations between first …